Medigen Vaccine Biologics has signed an MOU with Paraguay to conduct a Phase III trial for its COVID-19 vaccine candidate. The company and the foreign ministry confirmed the news on Tuesday.
Voice of Joanne Ou
Foreign ministry spokeswoman
We would be glad to see Medigen Vaccine Biologics and Paraguay’s Universidad Nacional de Asuncion collaborate on public health. Once our domestic vaccine is authorized for emergency use, the Taiwan government will throw its full weight behind the venture to support it.
Medigen has also signed an MOU with Vietnam to hold a Phase III trial. It’s applied for emergency use authorization in Taiwan, and plans to seek standard authorization in the European Union. Meanwhile Taiwan’s other COVID vaccine developer, United Biomedical, is preparing to release its Phase II results at the end of the July. United Biomedical plans to conduct its Phase III clinical trial in India.